| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084130732 |
| P356 | DOI | 10.1038/S41598-017-00606-W |
| P932 | PMC publication ID | 5428782 |
| P698 | PubMed publication ID | 28356599 |
| P2093 | author name string | Sarai Palanca Suela | |
| Rafael Botella Estrada | |||
| Rosa Ballester Sánchez | |||
| Blanca de Unamuno Bustos | |||
| Begoña Escutia Muñoz | |||
| Eduardo Nagore Enguídanos | |||
| Gema Pérez Simó | |||
| Inmaculada de Juan Jimenez | |||
| Margarita Llavador Ros | |||
| Mercedes Rodríguez Serna | |||
| Rosa Murria Estal | |||
| Victor Alegre de Miquel | |||
| P2860 | cites work | A landscape of driver mutations in melanoma | Q24603357 |
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma | Q24607661 | ||
| Melanoma genome sequencing reveals frequent PREX2 mutations | Q24610463 | ||
| Melanoma: from mutations to medicine | Q27024061 | ||
| Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. | Q27851483 | ||
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF | Q27853045 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor | Q33510817 | ||
| Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma | Q53777162 | ||
| Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma | Q54374929 | ||
| Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. | Q54706020 | ||
| Defining fast-growing melanomas | Q57664769 | ||
| A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance | Q33875566 | ||
| Field guide to next‐generation DNA sequencers | Q33904607 | ||
| Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
| Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. | Q34786717 | ||
| Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma | Q34898560 | ||
| Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations | Q35066201 | ||
| Exome sequencing identifies GRIN2A as frequently mutated in melanoma | Q35179796 | ||
| Comprehensive Molecular Profiling of Archival Bone Marrow Trephines Using a Commercially Available Leukemia Panel and Semiconductor-Based Targeted Resequencing | Q35722733 | ||
| Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase | Q36071877 | ||
| RAC1 P29S regulates PD-L1 expression in melanoma. | Q36362336 | ||
| Resistance to BRAF-targeted therapy in melanoma | Q38071800 | ||
| Clinical actionability enhanced through deep targeted sequencing of solid tumors | Q41519437 | ||
| Panel sequencing melanomas | Q41602739 | ||
| TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. | Q42456732 | ||
| Mutations in ERBB4 may have a minor role in melanoma pathogenesis | Q45799899 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 495 | |
| P577 | publication date | 2017-03-29 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel | |
| P478 | volume | 7 |
| Q54996932 | A Next-Generation Sequencing Primer-How Does It Work and What Can It Do? |
| Q89707410 | A Rare BRAF V600E mutation detected by Next Generation Sequencing in a superficial spreading melanoma: case report and potential diagnostic implications |
| Q92819972 | Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study |
| Q101121128 | Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients |
| Q89171764 | Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma |
| Q49617718 | Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma |
| Q46742817 | Intratumor and Intertumor Heterogeneity in Melanoma |
| Q92909854 | Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach |
| Q98771864 | Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications |
| Q92240577 | Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program |
| Q38617527 | Somatic mutation analysis in melanoma using targeted next generation sequencing |
| Q92571426 | Targetable driver mutations in multicentric reticulohistiocytosis |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q90611117 | The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas |
| Q64972523 | The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic. |
| Q92431785 | Whole transcriptome analysis reveals correlation of long noncoding RNA ZEB1-AS1 with invasive profile in melanoma |
Search more.